Accordig to Sandoz, the company has received marketing authorization in Estonia, Latvia and Lithuania for the 50-250 and 50-500 µg dosages of the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD. The inhaler is now approved in 13 European countries, as well as in Mexico and South Korea.
Sandoz Head of Global Respiratory Jan-Torsten Tews commented, “We look forward to launching this important new product in the Baltics in the near future and making it available to a steadily growing number of people suffering from asthma and COPD. This is an affordable and award winning new therapeutic option, developed in close collaboration with patients.”
The product originally known as VR315 was developed by Vectura and licensed to Sandoz in 2006. In 2010, Sandoz returned the US rights, which were acquired by an undisclosed pharmaceutical company in 2011.
Read the Sandoz press release.
